Emerging Infectious Disease ISSN: 1080-6059

H275Y Mutant Pandemic (H1N1) 2009 Virus in Immunocompromised Patients

Christian Renaud, Alexandre A. Boudreault, Jane Kuypers, Kathryn H. Lofy, Lawrence Corey, Michael J. Boeckh, and Janet A. Englund

Author affiliations: Author affiliations: Fred Hutchinson Cancer Research Center, Seattle, Washington, USA (C. Renaud, A.A. Boudreault, L. Corey, M.J. Boeckh, J.A. Englund); Seattle Children’s Hospital, Seattle (C. Renaud, J.A. Englund); University of Washington, Seattle (J. Kuypers, L. Corey, M.J. Boeckh, J.A. Englund); Washington State Department of Health, Shoreline, Washington, USA (K.H. Lofy)

Main Article

Figure

Viral kinetics in nasal washes and treatment data of 7 patients (patient nos. 1–7 shown top to bottom) with H275Y mutation of pandemic (H1N1) 2009 virus, Seattle Cancer Care Alliance, Seattle, Washington, USA, May 1, 2009–April 30, 2010. Black lines, pandemic (H1N1) 2009 viral load; red line, % H275Y mutant. OTV, oseltamivir; RBV, ribavirin; RTM, rimantadine; ZNV, zanamivir; PMV, peramivir; BAL, bronchoalveolar lavage.

Figure. Viral kinetics in nasal washes and treatment data of 7 patients (patient nos. 1–7 shown top to bottom) with H275Y mutation of pandemic (H1N1) 2009 virus, Seattle Cancer Care Alliance, Seattle, Washington, USA, May 1, 2009–April 30, 2010. Black lines, pandemic (H1N1) 2009 viral load; red line, % H275Y mutant. OTV, oseltamivir; RBV, ribavirin; RTM, rimantadine; ZNV, zanamivir; PMV, peramivir; BAL, bronchoalveolar lavage.

Main Article

Top of Page

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.